Selected Clinical Trials in Colorectal Cancer

Clinical

Trials Selected Clinical Trials in Colorectal Cancer Sponsor

Contact

Contact Information

Dana-Farber Cancer Institute/ National Cancer Institute

Jeffrey W. Clark, MD

617-724-0786

Memorial Sloan-Kettering Cancer Center/National Cancer Institute

Bruce D. Minsky, MD

212-639-6817

Phase III Randomized Study of Adjuvant Chemotherapy Comprising Fluorouracil, Leucovorin Calcium, and Oxaliplatin with Versus Without Bevacizumab in Patients with Resected Stage II or III Adenocarcinoma of the Colon

National Surgical Adjuvant Breast and Bowel Project/National Cancer Institute

Leonardo Forero

806-354-5875

Phase III Randomized Study of Adjuvant Oxaliplatin, Leucovorin Calcium, and Fluorouracil (FOLFOX4) Versus Bevacizumab and FOLFOX4 Versus Bevacizumab, Oxaliplatin, and Capecitabine in Patients with High-Risk Stage II or Stage III Colon Cancer

Jonsson Comprehensive Cancer Center/National Cancer Institute

Joel R. Hecht, MD

310-206-4303

A Phase II Study of First-Line Therapy with Bevacizumab and Cetuximab in Combination with FOLFOX6 in Patients with Metastatic Colorectal Cancer

Sarah Cannon Research Institute/Bristol-Myers-Squibb/ Genentech/Sanofi-Aventis

David R. Spigel, MD

615-329-7274

A Randomized, Open-Label, Controlled, Phase III Trial of Chemotherapy and Bevacizumab with and Without Panitumumab in the First-Line Treatment of Subjects with Metastatic Colorectal Cancer

Amgen

Amgen Call Center

866-572-6436

Phase II Study of Oxaliplatin, Capecitabine, and Bevacizumab as First-Line Treatment for Patients with Advanced Colorectal Cancer

Norris Comprehensive Cancer Center/Hoffmann-La Roche/Genentech

Syma Iqbal, MD

323-865-0820

A Phase II Study of Bevacizumab (Avastin™) and Erlotinib (Tarceva™) in Combination with FOLFOX for Patients with Untreated Metastatic Colorectal Cancer

Dana-Farber Cancer Institute/Brigham and Women's Hospital/Massachusetts General Hospital

Jeffrey Meyerhardt, MD

877-601-8601

Phase I Dose-Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-582664 in Combination with Full-Dose Erbitux in Patients with Advanced Colorectal Cancer Who Have Received No More Than 2 Prior Regimens for Metastatic Colorectal Cancer

Bristol-Myers-Squibb

Bristol-Myers-Squibb Call Center

866-892-1267 Ext. 212

Phase III Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients with Metastatic, EGFR-Positive Colorectal Cancer

ImClone Systems/Bristol-Myers-Squibb

Lee Schwartzberg, MD

901-683-0055 Ext. 1049

Phase II Study of Panitumumab in Patients with Metastatic Colorectal Cancer That Progressed During or After Prior Chemotherapy with Fluoropyrimidines, Irinotecan, and Oxaliplatin

Jonsson Comprehensive Cancer Center/National Cancer Institute

Joel R. Hecht, MD

310-206-6909

Duke Comprehensive Cancer Center/National Cancer Institute

Michael A. Morse, MD

919-681-3480

Vanderbilt University

David P. Carbone, MD, PhD

615-936-3524

National Cancer Institute

James Gulley, MD, PhD

301-496-9812

Trial Neoadjuvant Therapy Phase I Study of Neoadjuvant Bevacizumab, Fluorouracil, and External-Beam Radiotherapy in Patients with Stage II or III Rectal Cancer Phase II Pilot Study of Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Patients with Locally Advanced or Locally Recurrent Rectal Cancer Adjuvant Therapy

First-Line Metastatic Disease

Recurrent Metastatic Disease

Vaccine Therapy Phase I Study Denileukin Diftitox Followed by Active Immunotherapy Comprising Autologous Dendritic Cells Infected with Recombinant Fowlpox-CEA(6D)-TRICOM Vaccine in Patients with Metastatic CEA-Expressing Malignancies Phase I/II Study of Ras Peptide Cancer Vaccine with or Without Interleukin-2 in HLA-A2-1-Positive Patients with Locally Advanced or Metastatic Colorectal Cancer Phase II Pilot Study of Vaccination Comprising Recombinant Vaccinia-CEA-MUC1-TRICOM Vaccine, Recombinant Fowlpox-CEA-MUC-1-TRICOM Vaccine, and Sargramostim (GM-CSF) in Patients with Metastatic Carcinoma

Electronic forwarding or copying is a violation of US and International Copyright Laws. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1533-0028, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.

376 • Clinical Colorectal Cancer January 2006